BridgeBio Pharma Target of Unusually High Options Trading (NASDAQ:BBIO)

15 Sep 2026, 17:40 by Kim Johansen · The Markets Daily

BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) was the target of unusually large options trading activity on Tuesday. Stock investors purchased 9,739 put options on the stock. This represents an increase of approximately 584% compared to the typical daily volume of 1,424 put options.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. TD Cowen lifted their target price on BridgeBio Pharma from $95.00 to $110.00 and gave the company a “buy” rating in a research report on Tuesday, August 11th. Canaccord Genuity Group upped their price objective on BridgeBio Pharma from $104.00 to $106.00 and gave the company a “buy” rating in a report on Wednesday, August 12th. Bank of America boosted their price target on BridgeBio Pharma from $101.00 to $104.00 and gave the company a “buy” rating in a research note on Tuesday, August 11th. Citigroup upped their price target on shares of BridgeBio Pharma from $82.00 to $93.00 and gave the stock a “neutral” rating in a report on Thursday, July 16th. Finally, Mizuho lifted their target price on BridgeBio Pharma from $96.00 to $110.00 and gave the company an “outperform” rating in a research report on Tuesday, September 1st. Twenty research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $102.61.

Get Our Latest Research Report on BBIO

BridgeBio Pharma Stock Performance

Shares of NASDAQ BBIO traded down $5.13 during midday trading on Tuesday, reaching $67.25. The stock had a trading volume of 1,906,072 shares, compared to its average volume of 2,866,319. BridgeBio Pharma has a twelve month low of $48.78 and a twelve month high of $93.42. The company’s 50 day moving average price is $80.54 and its 200 day moving average price is $73.74. The firm has a market cap of $13.15 billion, a price-to-earnings ratio of -18.77 and a beta of 0.97.

BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.78) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.20). The firm had revenue of $243.68 million for the quarter, compared to analysts’ expectations of $220.91 million. The company’s revenue for the quarter was up 120.4% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.95) EPS. Equities analysts forecast that BridgeBio Pharma will post -2.64 earnings per share for the current fiscal year.

Insider Buying and Selling at BridgeBio Pharma

In other BridgeBio Pharma news, CEO Neil Kumar sold 10,000 shares of the stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $84.03, for a total value of $840,300.00. Following the completion of the sale, the chief executive officer directly owned 505,686 shares in the company, valued at $42,492,794.58. This represents a 1.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Hannah Valantine sold 2,196 shares of the stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $68.57, for a total transaction of $150,579.72. Following the sale, the director directly owned 9,259 shares of the company’s stock, valued at $634,889.63. This represents a 19.17% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 257,103 shares of company stock valued at $21,579,211 over the last three months. Insiders own 14.23% of the company’s stock.

Institutional Investors Weigh In On BridgeBio Pharma

Several institutional investors and hedge funds have recently added to or reduced their stakes in BBIO. Integrated Wealth Concepts LLC bought a new position in BridgeBio Pharma in the 2nd quarter valued at $52,000. IFP Advisors Inc lifted its holdings in BridgeBio Pharma by 44.8% during the second quarter. IFP Advisors Inc now owns 1,160 shares of the company’s stock valued at $86,000 after purchasing an additional 359 shares during the last quarter. Squarepoint Ops LLC raised its holdings in BridgeBio Pharma by 114.2% during the 2nd quarter. Squarepoint Ops LLC now owns 1,191,732 shares of the company’s stock valued at $88,760,000 after acquiring an additional 635,408 shares during the period. Arizona State Retirement System lifted its holdings in shares of BridgeBio Pharma by 2.0% in the second quarter. Arizona State Retirement System now owns 40,501 shares of the company’s stock worth $3,017,000 after buying an additional 802 shares in the last quarter. Finally, Nykredit A S purchased a new stake in shares of BridgeBio Pharma in the second quarter worth $410,000. Hedge funds and other institutional investors own 99.85% of the company’s stock.

About BridgeBio Pharma

(Get Free Report)

BridgeBio Pharma, Inc is a biopharmaceutical company focused on discovering, developing and delivering medicines for patients with genetically driven diseases and cancers. Founded in 2015, the company operates through a group of subsidiary biotechnology businesses, each generally focused on a specific disease area or therapeutic program.